| Literature DB >> 29686887 |
Neelakanteswar Aluru1, Sibel I Karchner1, Keegan S Krick1, Wei Zhu2, Jiang Liu2.
Abstract
There is growing evidence that environmental toxicants can affect various physiological processes by altering DNA methylation patterns. However, very little is known about the impact of toxicant-induced DNA methylation changes on gene expression patterns. The objective of this study was to determine the genome-wide changes in DNA methylation concomitant with altered gene expression patterns in response to 3, 3', 4, 4', 5-pentachlorobiphenyl (PCB126) exposure. We used PCB126 as a model environmental chemical because the mechanism of action is well-characterized, involving activation of aryl hydrocarbon receptor, a ligand-activated transcription factor. Adult zebrafish were exposed to 10 nM PCB126 for 24 h (water-borne exposure) and brain and liver tissues were sampled at 7 days post-exposure in order to capture both primary and secondary changes in DNA methylation and gene expression. We used enhanced Reduced Representation Bisulfite Sequencing and RNAseq to quantify DNA methylation and gene expression, respectively. Enhanced reduced representation bisulfite sequencing analysis revealed 573 and 481 differentially methylated regions in the liver and brain, respectively. Most of the differentially methylated regions are located more than 10 kilobases upstream of transcriptional start sites of the nearest neighboring genes. Gene Ontology analysis of these genes showed that they belong to diverse physiological pathways including development, metabolic processes and regeneration. RNAseq results revealed differential expression of genes related to xenobiotic metabolism, oxidative stress and energy metabolism in response to polychlorinated biphenyl exposure. There was very little correlation between differentially methylated regions and differentially expressed genes suggesting that the relationship between methylation and gene expression is dynamic and complex, involving multiple layers of regulation.Entities:
Keywords: PCBs; RNAseq; brain; enhanced reduced representation bisulfite sequencing (eRRBS); liver
Year: 2018 PMID: 29686887 PMCID: PMC5905506 DOI: 10.1093/eep/dvy005
Source DB: PubMed Journal: Environ Epigenet ISSN: 2058-5888
Figure 1:PCB126-induced cyp1a gene expression in the liver (A) and brain (B). Cyp1a expression relative to the reference gene was calculated using the delta Ct method. β-Actin was used as a reference gene. * Represents significant difference from DMSO control (One-way ANOVA; P < 0.01)
Figure 2:Tissue-specific DNA methylation profiles and their genomic location. Percentage of methylation levels in the proximal promoter regions (A) and CpG islands (B) in the liver and brain are plotted. (C) Percentage of 300 bp tiles overlapping with different genomic regions. These plots are based on the tiles represented in all samples. Proximal (up to 5 kb upstream) and distal promoter (>5 kb) regions are classified based on the distance from the transcriptional start site
Figure 3:PCB126-induced tissue-specific changes in DNA methylation. Volcano plots showing DMRs in response to PCB126 exposure in the liver (A) and brain (B). Percent methylation difference (x-axis) between PCB126 and Control are plotted against q-value (y-axis). Red vertical lines represent the 25% methylation difference and the blue horizontal line represents a q-value of 0.05, which are used as a statistical cutoff in differential methylation analysis. Each green and red spot represents a statistically significant hypo and hypermethylated region, respectively
Figure 4:GO term analysis of DMRs in the liver (A, C) and brain (B, D). Top panel represents GO biological process terms and the bottom panel contains the GO molecular function terms. GO term analysis was performed on DMRs using GREAT. Only statistically significant GO terms are shown. The fold enrichment of GO terms and the genes associated with each term are provided in the Supplementary Material
Figure 5:Tissue-specific gene expression changes. MA plots showing the DEGs in the liver (A) and brain (B). Horizontal blue lines represent fold change of ± 2. Each red spot represent a statistically differentially expressed gene
Representative xenobiotic responsive genes differentially expressed in liver and brain in response to PCB126 exposure
| Gene name | Gene symbol | Liver | Brain | ||
|---|---|---|---|---|---|
| logFC | FDR | logFC | FDR | ||
| AHR repressor a | 10.677 | 7.21E–46 | 3.850 | 1.12E–02 | |
| AHR repressor b | 7.500 | 4.89E–04 | 2.669 | 3.68E–02 | |
| AHR interacting protein | 0.553 | 3.90E–02 | |||
| AHR nuclear translocator-like 1a | –0.694 | 2.71E–02 | |||
| AHR nuclear translocator-like 1b | –0.792 | 3.38E–02 | |||
| AHR nuclear translocator-like 2 | –1.758 | 2.75E–03 | –1.033 | 2.53E–02 | |
| Cytochrome P4501a | 5.420 | 3.40E–20 | 8.571 | 8.60E–85 | |
| Cytochrome P4501b1 | 7.750 | 1.35E–16 | 1.834 | 3.11E–03 | |
| Cytochrome P450, family 1, subfamily C, polypeptide 1 | 5.433 | 6.30E–17 | 4.745 | 7.26E–06 | |
| Cytochrome P450, family 1, subfamily C, polypeptide 2 | 2.887 | 2.44E–06 | 3.058 | 6.81E–03 | |
| Cytochrome P450, family 2, subfamily AA, polypeptide 12 | 1.443 | 3.88E–02 | |||
| Cytochrome P450, family 2, subfamily AA, polypeptide 4 | 2.662 | 2.04E–02 | |||
| Cytochrome P450, family 2, subfamily K, polypeptide 22 | –5.654 | 2.50E–02 | |||
| Cytochrome P450, family 2, subfamily K, polypeptide 31 | –5.169 | 3.10E–07 | |||
| Cytochrome P450, family 2, subfamily K, polypeptide 6 | 8.607 | 1.52E–02 | |||
| Cytochrome P450, family 2, subfamily X, polypeptide 10.2 | 3.495 | 2.32E–10 | |||
| Cytochrome P450, family 2, subfamily AD, polypeptide 3 | 1.055 | 1.79E–02 | |||
| Cytochrome P450, family 2, subfamily P, polypeptide 6 | 1.005 | 6.51E–03 | |||
| Cytochrome P450, family 2, subfamily V, polypeptide 1 | 1.348 | 9.56E–03 | |||
| Cytochrome P450, family 26, subfamily b, polypeptide 1 | 0.985 | 9.56E–03 | |||
| Glutathione S-transferase theta 1b | 1.349 | 4.30E–02 | |||
| Microsomal glutathione S-transferase 3b | 2.050 | 7.38E–04 | 0.762 | 1.18E–02 | |
| Glutathione S-transferase theta 1a | 3.983 | 3.73E–02 | |||
| Glutathione S-transferase mu, tandem duplicate 1 | 0.619 | 3.15E–02 | |||
| Glutathione S-transferase rho | 0.768 | 3.90E–02 | |||
| Glutathione S-transferase pi 1 | 0.883 | 3.43E–02 | |||
| Glutamate-cysteine ligase, modifier subunit | 1.779 | 1.52E–03 | |||
| Glutathione reductase | 1.498 | 3.79E–03 | |||
| Glucose-6-phosphate dehydrogenase | 1.610 | 1.96E–02 | |||
| NAD(P)H dehydrogenase, quinone 1 | 1.951 | 3.42E–02 | |||
| Kelch-like ECH-associated protein 1b | 1.308 | 4.11E–02 | |||
| UDP glucuronosyltransferase 1 family, polypeptide B5 | 1.633 | 2.20E–02 | |||
| UDP glucuronosyltransferase 1 family, polypeptide B1 | 1.667 | 6.72E–03 | |||
| UDP glucuronosyltransferase 1 family, polypeptide B2 | –2.217 | 3.98E–02 | |||
| UDP glucuronosyltransferase 1 family, polypeptide B7 | –2.779 | 8.30E–05 | |||
| UDP glucuronosyltransferase 5 family, polypeptide C2 | –2.099 | 1.03E–02 | |||
| UDP glucuronosyltransferase 1 family, polypeptide A6 | 4.251 | 3.13E–02 | |||
| Phosphogluconate dehydrogenase | 1.856 | 4.99E–03 | |||
GO and KEGG pathway analysis of DEGs in the liver (A) Upregulated genes and (B) downregulated genes in the liver were analysed separately for enrichment of GO biological process and molecular function terms and KEGG pathways
| A | ||
|---|---|---|
| Term ID | Name | Adjusted |
| GO: 0009410 | Response to xenobiotic stimulus | 0.002 |
| GO: 0032190 | Acrosin binding | 0.000152 |
| KEGG: 04110 | Cell cycle | 0.0000199 |
| B | ||
| Term ID | Name | Adjusted |
| GO: 0015669 | Gas transport | 0.0000129 |
| GO: 0006820 | Anion transport | 0.000632 |
| GO: 0010873 | Positive regulation of cholesterol esterification | 0.00185 |
| GO: 0033700 | Phospholipid efflux | 0.00185 |
| GO: 0065005 | Protein-lipid complex assembly | 0.00185 |
| GO: 0055088 | Lipid homeostasis | 0.00365 |
| GO: 0006695 | Cholesterol biosynthetic process | 0.0141 |
| GO: 0015248 | Sterol transporter activity | 0.00123 |
| GO: 0060228 | Phosphatidylcholine-sterol-O-acyltransferase activator activity | 0.00185 |
| GO: 0005344 | Oxygen transporter activity | 0.00365 |
| GO: 0019825 | Oxygen binding | 0.00365 |
| GO: 0020037 | Heme binding | 0.0376 |
| GO: 0015485 | Cholesterol binding | 0.0417 |
| GO: 0005215 | Transporter activity | 0.0463 |
| KEGG: 00910 | Nitrogen metabolism | 0.0386 |
GO and KEGG pathway analysis of DEGs in the brain (A) Upregulated genes and (B) downregulated genes in the brain were analysed separately for enrichment of GO biological process and molecular funtion terms and KEGG pathways
| A | ||
|---|---|---|
| Term ID | GO term | Adjusted |
| GO: 0006412 | Translation | 0.0000253 |
| GO: 0009410 | Response to xenobiotic stimulus | 0.0000854 |
| GO: 0003012 | Muscle system process | 0.000151 |
| GO: 0060326 | Cell chemotaxis | 0.00487 |
| GO: 0045861 | Negative regulation of proteolysis | 0.0158 |
| GO: 0043902 | Positive regulation of multi-organism process | 0.0161 |
| GO: 0009605 | Response to external stimulus | 0.024 |
| GO: 0003735 | Structural constituent of ribosome | 9.07E–13 |
| GO: 0003779 | Actin binding | 0.0000803 |
| GO: 0032190 | Acrosin binding | 0.0299 |
| KEGG: 03010 | Ribosome | 1.66E–11 |
| KEGG: 00980 | Metabolism of xenobiotics by cytochrome P450 | 0.000786 |
| B | ||
| Term ID | GO term | Adjusted |
| GO: 0016043 | Cellular component organization | 2.28E–15 |
| GO: 0060627 | Regulation of vesicle-mediated transport | 0.00154 |
| GO: 0043087 | Regulation of GTPase activity | 0.0023 |
| GO: 0006836 | Neurotransmitter transport | 0.00343 |
| GO: 0035556 | Intracellular signal transduction | 0.00659 |
| GO: 0000902 | Cell morphogenesis | 0.0188 |
| GO: 0017111 | Nucleoside-triphosphatase activity | 0.00641 |
| GO: 0015631 | Tubulin binding | 6.44E–11 |
| GO: 0008047 | Enzyme activator activity | 0.00309 |
| GO: 0005200 | Structural constituent of cytoskeleton | 0.00375 |
| GO: 0098772 | Molecular function regulator | 0.0042 |
| KEGG: 04320 | Dorso-ventral axis formation | 0.0043 |
| KEGG: 04068 | FoxO signaling pathway | 0.0147 |
| KEGG: 03015 | mRNA surveillance pathway | 0.0167 |
| KEGG: 04012 | ErbB signaling pathway | 0.0368 |
Relationship between DMRs and DEGs (A) List of genes in the liver (A) and brain (B) that are both differentially methylated and differentially expressed. Spearman correlation coefficient was not statistically significant (r2 = 0.2719 for liver and 0.0078 for brain). There is an inverse relationship between DNA methylation (Meth. diff) and gene expression (logFC) for the genes highlighted in red